Forskning ved Københavns Universitet - Københavns Universitet

Forside

Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Bezlotoxumab for prevention of Clostridium difficile infection recurrence : Distinguishing relapse from reinfection with whole genome sequencing. / Zeng, Zhen; Zhao, Hailong; Dorr, Mary Beth; Shen, Judong; Wilcox, Mark H.; Poxton, Ian R.; Guris, Dalya; Li, Junhua; Shaw, Peter M.

I: Anaerobe, Bind 61, 102137, 2020.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Zeng, Z, Zhao, H, Dorr, MB, Shen, J, Wilcox, MH, Poxton, IR, Guris, D, Li, J & Shaw, PM 2020, 'Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing', Anaerobe, bind 61, 102137. https://doi.org/10.1016/j.anaerobe.2019.102137

APA

Zeng, Z., Zhao, H., Dorr, M. B., Shen, J., Wilcox, M. H., Poxton, I. R., ... Shaw, P. M. (2020). Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing. Anaerobe, 61, [102137]. https://doi.org/10.1016/j.anaerobe.2019.102137

Vancouver

Zeng Z, Zhao H, Dorr MB, Shen J, Wilcox MH, Poxton IR o.a. Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing. Anaerobe. 2020;61. 102137. https://doi.org/10.1016/j.anaerobe.2019.102137

Author

Zeng, Zhen ; Zhao, Hailong ; Dorr, Mary Beth ; Shen, Judong ; Wilcox, Mark H. ; Poxton, Ian R. ; Guris, Dalya ; Li, Junhua ; Shaw, Peter M. / Bezlotoxumab for prevention of Clostridium difficile infection recurrence : Distinguishing relapse from reinfection with whole genome sequencing. I: Anaerobe. 2020 ; Bind 61.

Bibtex

@article{376722005d7e4c9aa3b2f108acf83a26,
title = "Bezlotoxumab for prevention of Clostridium difficile infection recurrence: Distinguishing relapse from reinfection with whole genome sequencing",
abstract = "Background: Bezlotoxumab has been shown to prevent Clostridium difficile infection recurrence (rCDI) in high-risk patients. Methods: We used whole genome sequencing to estimate the impact of bezlotoxumab on same-strain relapse or new-strain reinfection in MODIFY I/II trials. Reinfection with a new strain and relapse with the same strain were differentiated by the comparison of ribotype (RT) and pair-wise single-nucleotide whole genome sequencing (WGS) variations (PWSNV). Relapse was assigned if the baseline RT and the RT isolated during rCDI were the same, and if PWSNVs were ≤ 2. Reinfection was assigned if the baseline RT and the RT isolated during rCDI were different, or if the RT was the same but PWSNVs were > 10. Unknown status was assigned if the RT was the same but PWSNVs were 3–10. Results: 259 rCDI events were evaluable (50 [19.3{\%}] reinfection; 198 [76.4{\%}] relapse). The proportion of relapses was higher for ribotype 027 (84.5{\%}) compared with other ribotypes (74.1{\%}). Cumulative incidence of relapse was significantly lower for bezlotoxumab versus no bezlotoxumab (p < 0.0001), with a non-significant trend towards reduction for reinfection (p = 0.14). Conclusion: Bezlotoxumab treatment significantly reduced the rate of CDI relapse versus a regimen without bezlotoxumab. (NCT01241552/NCT01513239).",
keywords = "Bezlotoxumab, Clostridium difficile infection, Recurrence, Reinfection, Relapse, Single nucleotide polymorphism, Whole genome sequencing",
author = "Zhen Zeng and Hailong Zhao and Dorr, {Mary Beth} and Judong Shen and Wilcox, {Mark H.} and Poxton, {Ian R.} and Dalya Guris and Junhua Li and Shaw, {Peter M.}",
year = "2020",
doi = "10.1016/j.anaerobe.2019.102137",
language = "English",
volume = "61",
journal = "Anaerobe",
issn = "1075-9964",
publisher = "Academic Press",

}

RIS

TY - JOUR

T1 - Bezlotoxumab for prevention of Clostridium difficile infection recurrence

T2 - Distinguishing relapse from reinfection with whole genome sequencing

AU - Zeng, Zhen

AU - Zhao, Hailong

AU - Dorr, Mary Beth

AU - Shen, Judong

AU - Wilcox, Mark H.

AU - Poxton, Ian R.

AU - Guris, Dalya

AU - Li, Junhua

AU - Shaw, Peter M.

PY - 2020

Y1 - 2020

N2 - Background: Bezlotoxumab has been shown to prevent Clostridium difficile infection recurrence (rCDI) in high-risk patients. Methods: We used whole genome sequencing to estimate the impact of bezlotoxumab on same-strain relapse or new-strain reinfection in MODIFY I/II trials. Reinfection with a new strain and relapse with the same strain were differentiated by the comparison of ribotype (RT) and pair-wise single-nucleotide whole genome sequencing (WGS) variations (PWSNV). Relapse was assigned if the baseline RT and the RT isolated during rCDI were the same, and if PWSNVs were ≤ 2. Reinfection was assigned if the baseline RT and the RT isolated during rCDI were different, or if the RT was the same but PWSNVs were > 10. Unknown status was assigned if the RT was the same but PWSNVs were 3–10. Results: 259 rCDI events were evaluable (50 [19.3%] reinfection; 198 [76.4%] relapse). The proportion of relapses was higher for ribotype 027 (84.5%) compared with other ribotypes (74.1%). Cumulative incidence of relapse was significantly lower for bezlotoxumab versus no bezlotoxumab (p < 0.0001), with a non-significant trend towards reduction for reinfection (p = 0.14). Conclusion: Bezlotoxumab treatment significantly reduced the rate of CDI relapse versus a regimen without bezlotoxumab. (NCT01241552/NCT01513239).

AB - Background: Bezlotoxumab has been shown to prevent Clostridium difficile infection recurrence (rCDI) in high-risk patients. Methods: We used whole genome sequencing to estimate the impact of bezlotoxumab on same-strain relapse or new-strain reinfection in MODIFY I/II trials. Reinfection with a new strain and relapse with the same strain were differentiated by the comparison of ribotype (RT) and pair-wise single-nucleotide whole genome sequencing (WGS) variations (PWSNV). Relapse was assigned if the baseline RT and the RT isolated during rCDI were the same, and if PWSNVs were ≤ 2. Reinfection was assigned if the baseline RT and the RT isolated during rCDI were different, or if the RT was the same but PWSNVs were > 10. Unknown status was assigned if the RT was the same but PWSNVs were 3–10. Results: 259 rCDI events were evaluable (50 [19.3%] reinfection; 198 [76.4%] relapse). The proportion of relapses was higher for ribotype 027 (84.5%) compared with other ribotypes (74.1%). Cumulative incidence of relapse was significantly lower for bezlotoxumab versus no bezlotoxumab (p < 0.0001), with a non-significant trend towards reduction for reinfection (p = 0.14). Conclusion: Bezlotoxumab treatment significantly reduced the rate of CDI relapse versus a regimen without bezlotoxumab. (NCT01241552/NCT01513239).

KW - Bezlotoxumab

KW - Clostridium difficile infection

KW - Recurrence

KW - Reinfection

KW - Relapse

KW - Single nucleotide polymorphism

KW - Whole genome sequencing

U2 - 10.1016/j.anaerobe.2019.102137

DO - 10.1016/j.anaerobe.2019.102137

M3 - Journal article

C2 - 31846705

AN - SCOPUS:85076467137

VL - 61

JO - Anaerobe

JF - Anaerobe

SN - 1075-9964

M1 - 102137

ER -

ID: 235587490